Raymond James Financial
LGND icon

Raymond James Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Raymond James Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.65M Sell
17,869
-389
-2% -$91.7K ﹤0.01% 2637
2026
Q1 		$3.65M Sell
18,258
-498
-3% -$98.5K ﹤0.01% 2853
2025
Q4 		$3.55M Sell
18,756
-104
-0.6% -$20K ﹤0.01% 2798
2025
Q3 		$3.34M Sell
18,860
-1,237
-6% -$184K ﹤0.01% 2770
2025
Q2 		$2.28M Sell
20,097
-40
-0.2% -$4.28K ﹤0.01% 2976
2025
Q1 		$2.12M Sell
20,137
-1,693
-8% -$191K ﹤0.01% 2948
2024
Q4 		$2.34M Buy
+21,830
New +$2.47M ﹤0.01% 2852

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's LGND Position: Q2 2026 in Review

Raymond James Financial reduced its Ligand Pharmaceuticals (LGND) stake by 2.1% in Q2 2026, selling an estimated $91.7K and leaving 17,869 shares worth $5.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2637.

Raymond James Financial first reported a position in LGND in Q4 2024 and has held it in 7 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Raymond James Financial held 17,869 shares of Ligand Pharmaceuticals worth $5.65M as of Q2 2026.
  • Raymond James Financial sold 389 Ligand Pharmaceuticals shares in Q2 2026, an estimated $91.7K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2637 holding.
  • Raymond James Financial first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.